# Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

> **NCT00187109** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 40 (—)

## Conditions studied

- Germ Cell Tumors
- Hepatic Cancer
- Neuroblastoma
- Osteosarcoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** Recombinant Human Thrombopoietin

## Key facts

- **NCT ID:** NCT00187109
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00187109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00187109, "Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00187109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*